MIR548I3: A Potential Drug Target and Biomarker (G100302186)
MIR548I3: A Potential Drug Target and Biomarker
MIR548I3, a protein encoded by the MySQL gene, is a member of the interleukin-8 (IL-8) receptor family. It is highly expressed in various tissues and has been implicated in various biological processes, including inflammation, immune response, and cell survival. The MIR548I3 gene has also been implicated in cancer progression and has been identified as a potential drug target. In this article, we will discuss the potential drug target and biomarker properties of MIR548I3, as well as its current research status and potential clinical applications.
The MIR548I3 gene encodes a protein that is composed of 1,942 amino acids. The protein has a molecular weight of 21.1 kDa and a pre-fusion calculated pI of 9.97. MIR548I3 is highly expressed in various tissues, including muscle, liver, and brain. It is also expressed in various cell types, including immune cells,Endometrial cells, and epithelial cells.
MIR548I3 has been shown to play a role in various biological processes. It is a potent chemoattractant for immune cells and has been shown to induce the migration of various cell types, including neutrophils and T cells. MIR548I3 has also been shown to promote the production of pro-inflammatory cytokines, such as TNF-伪 and IL-8, and to enhance the production of anti-inflammatory cytokines, such as IL-10.
In addition to its role in inflammation, MIR548I3 has also been implicated in various other biological processes, including cell survival and angiogenesis. It has been shown to promote the growth and survival of various cell types, including cancer cells, and to contribute to the development of cancer. MIR548I3 has also been shown to promote the formation of blood-brain barriers and to contribute to the development of neurodegenerative diseases.
The MIR548I3 gene has also been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, MIR548I3 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. It has also been shown to contribute to the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.
Due to its involvement in various biological processes, MIR548I3 has potential as a drug target. The MIR548I3 protein has been shown to interact with various molecules, including the protein PD-L1 and the tyrosine kinase inhibitor, PD-033291. These interactions suggest that MIR548I3 may be a useful target for drugs that target the immune system, cell signaling pathways, or protein interactions.
In addition to its potential as a drug target, MIR548I3 has also been identified as a potential biomarker. The MIR548I3 protein has been shown to be expressed in various tissues and has been used as a marker for cancer diagnosis and prognosis. It has also been shown to be a potential biomarker for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.
MIR548I3 has also been shown to have potential clinical applications. For example, the MIR548I3 gene has been targeted for cancer treatment by using small molecules and antibodies to specifically target MIR548I3. These treatments have been shown to inhibit the growth and survival of cancer cells, including MIR548I3-expressing cells.
In addition to its potential as a drug target and biomarker, MIR548I3 has also been shown to have potential as a diagnostic tool. The MIR548I3 protein has been used as a
Protein Name: MicroRNA 548i-3
The "MIR548I3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR548I3 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR548I4 | MIR548J | MIR548K | MIR548L | MIR548M | MIR548N | MIR548O | MIR548O2 | MIR548P | MIR548Q | MIR548S | MIR548T | MIR548U | MIR548V | MIR548W | MIR548X | MIR548Y | MIR549A | MIR550A1 | MIR550A2 | MIR550A3 | MIR550B1 | MIR550B2 | MIR551A | MIR551B | MIR552 | MIR553 | MIR554 | MIR555 | MIR556 | MIR557 | MIR5571 | MIR5572 | MIR5579 | MIR558 | MIR5580 | MIR5581 | MIR5582 | MIR5583-1 | MIR5584 | MIR5585 | MIR5586 | MIR5587 | MIR5588 | MIR5589 | MIR559 | MIR5590 | MIR5591 | MIR561 | MIR562 | MIR563 | MIR564 | MIR566 | MIR567 | MIR568 | MIR5680 | MIR5681A | MIR5681B | MIR5682 | MIR5683 | MIR5684 | MIR5685 | MIR5687 | MIR5688 | MIR5689 | MIR569 | MIR5690 | MIR5691 | MIR5692A1 | MIR5692A2 | MIR5692B | MIR5692C1 | MIR5692C2 | MIR5693 | MIR5694 | MIR5695 | MIR5696 | MIR5697 | MIR5698 | MIR5699 | MIR570 | MIR5700 | MIR5701-1 | MIR5701-2 | MIR5701-3 | MIR5702 | MIR5703 | MIR5704 | MIR5705 | MIR5706 | MIR5707 | MIR5708 | MIR570HG | MIR571 | MIR572 | MIR573 | MIR5739 | MIR574 | MIR575 | MIR576
